Why did Taro not pursue a sale earlier? On the facts available to us, it appears that your treatment of Taro Ireland in Taro's financial statements has, for years, allowed management to present higher profits (or lower losses) to Taro's shareholders. By capitalizing Taro Ireland's operating costs, you were able to capitalize such costs as part of Taro Ireland's fixed asset value on Taro's consolidated balance sheet (as appears to be the case in the last annual report filed by Taro). Then, it appears that you made a conscious decision to write down the value of Taro Ireland in the unaudited financial statements for 2006, presumably because this enabled Taro to lump the write-down together with other line items in Taro's worst financial statements ever. To a rational onlooker, it would seem that this was done in the hopes that Taro's shareholders would fail to notice it as a separate item. This is precisely the type of accounting gamesmanship that we have come to expect from you and your management. Now, you conveniently claim that selling Taro Ireland will help Taro show higher profits. If retaining Taro Ireland was in the interests of Taro's shareholders earlier, why is that not the case now?
Taro Ireland's New Products; Potential Revenue. In our view, now is not
the time to sell. Things are finally looking up for Taro Ireland; the Irish
authorities have approved, or are in the process of approving, a number of
products. These products can provide wide access to European markets, and
selling now coul
|SOURCE Sun Pharmaceutical Industries Ltd.|
Copyright©2008 PR Newswire.
All rights reserved